Q&A with Dr. Lisa Butterfield, PhD: Cancer Vaccines & Adoptive Cell Transfer

Dr. Lisa Butterfield, PhD recently joined the Parker Institute for Cancer Immunotherapy as Vice President focusing on cell therapies while she continues her independent cancer vaccine research as an Adjunct Professor of Microbiology and Immunology at the University of California,...

Identifying Signaling Pathways and Biomarkers in Autoimmune Diseases

As efforts in developing targeted therapies for autoimmune disease are rapidly advancing in basic research, scientists aim to validate immunology-relevant signaling pathways and uncover new intracellular molecules as potential drug targets. The NanoString® nCounter® Autoimmune Profiling and Immunology panels are...

/ June 24, 2019

New Biology-Driven Drug Discoveries Needed for Treating of Alzheimer’s

Alzheimer’s disease (AD) is a slowly progressing neurodegenerative disorder that affects millions of people worldwide, leaving behind an immense psychological, emotional, and financial burden on patients, caregivers, and healthcare systems. There are no existing therapies to prevent the onset or...

/ June 17, 2019

Q&A with Dr. Oliver Brain: Unintended Consequences Create a Unique Opportunity to Study Inflammatory Bowel Disease.

Oliver Brain, MRCP, PhD, is a principal investigator at the University of Oxford, Nuffield Department of Clinical Medicine, and a recent winner of an nCounter® Autoimmune Profiling Panel through a NanoString® Grant Program. He took time out from treating patients...

Nanostring Scientists Reveal the “Secret Sauce” in Lysate Protocol Development

https://youtu.be/1q9QHGaeLY4 My name is Chris Merritt. I am a Senior Scientist at NanoString Technologies and work in the R&D division. I've been here for five years now. There was one very specific change we had to make to this lysate...

/ May 29, 2019